PRA Expert to Speak at Drug Safety Conference

Strategies and Tools for Signal Detection

News provided by

Apr 17, 2012, 09:00 ET

RALEIGH, N.C., April 17, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that the head of our Safety and Risk Management (SRM) group will chair a breakout session and speak at the World Drug Safety Congress being held in Boston, MA from 18-20 April 2012. PRA will also host an exhibit at booth #4, where PRA representatives will be available to discuss our successful approach to drug development programs.

On 18 April at 1:10PM EDT, Dr. Sabine Richter, PRA's Vice President of SRM, will chair and provide opening remarks for the first breakout stream, "Risk Management Strategies." In addition, Dr. Richter will also give a presentation titled, "Pre-approval Signal Detection" at 1:45PM. She will review the relevant regulations and guidelines, clinical data challenges, operational considerations and tools for signal detection and confirmation.

Dr. Richter has over 20 years of research experience in the pharmaceutical and CRO industries as well as in academia. As vice president, she is responsible for all aspects of PRA's safety and risk management services. In her career, Dr. Richter has held various positions in project management, clinical operations, quality management and strategic proposals and contracts.

PRA provides safety and risk management services during the entire product life cycle. PRA's SRM team of more than 140 experts is available to our clients for consultancy as well as routine and specialty pharmacovigilance services. The majority of these staff members are either healthcare professionals (nurses, pharmacists, physicians) or life scientists. PRA has four Drug Safety Centers located in Germany, the UK, the US and Brazil.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected] or call our Global Headquarters.

SOURCE PRA